News from shield therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

17 Jun, 2016, 09:00 BST Feraccru® (ferric maltol) Launched in the UK for the Treatment of Adults with Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease

Latest oral iron treatment is effective with a safety profile comparable to placebo in patients who have failed oral ferrous treatments Shield...


07 May, 2015, 07:00 BST Phosphate Therapeutics Announces Positive Results in the PEACH Pivotal Study of its Novel Phosphate Binder (PT20) for the Treatment of hyperphosphataemia

Phosphate Therapeutics Limited ("Phosphate Therapeutics"), a development-stage specialty pharmaceuticals company, today announces positive results...


07 Jan, 2015, 07:00 GMT Shield Therapeutics Announces the Acceptance for Review by the European Medicines Agency of the Marketing Authorisation Application for Feraccru®

~ Shield seeks approval of Feraccru for the treatment of iron deficiency anaemia ~ Shield Therapeutics (Shield), an independent pharmaceutical...


04 Feb, 2014, 07:00 GMT Shield Therapeutics Announces Acceptance of ST10 Abstract for Presentation at ECCO Congress 2014

Shield Therapeutics (Shield), an independent specialty pharmaceutical company, today announces the acceptance of the first peer-reviewed abstract...


07 Jan, 2014, 07:00 GMT Shield Therapeutics' ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease

~ ST10 strongly demonstrates potential to be (1) the only effective oral treatment for ferrous intolerant IDA patients and (2) an effective...


16 Dec, 2013, 07:00 GMT FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today...


12 Nov, 2013, 07:00 GMT Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today...


23 Oct, 2013, 09:00 BST Shield Therapeutics to Attend BIO-Europe® 2013

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today...


24 Jun, 2013, 07:00 BST Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of...


12 Oct, 2011, 07:00 BST Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10

- Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn's disease - Shield Therapeutics...


01 Jun, 2011, 08:00 BST Shield Therapeutics Raises EUR8.2 Million From Inventages Venture Capital via Series A Institutional Round

- New Investment to Further Fund the Phase III Clinical Programme of ST10-021 in Iron Deficiency Anaemia Shield Therapeutics (Shield), the...


07 Jan, 2011, 12:00 GMT Shield Therapeutics to Present at the Biotech Showcase 2011

Shield Holdings AG (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital ...